As various maintenance therapies (immunotherapy, ADCs) are integrated into endometrial cancer treatment, the next major clinical question is defining how long these agents need to be continued to maximize benefit while minimizing long-term toxicity and patient burden.

Depression is now considered the fourth major risk factor for coronary artery disease, alongside hypertension, high cholesterol, and diabetes. This positions it not just as a mental health condition but as a direct physiological threat to cardiovascular health, making other illnesses worse.

Current Quality of Life (QoL) assessments in cancer trials fail to capture severe, long-term toxicities. They are designed for short-term effects and data collection often ceases after a patient experiences a life-changing adverse event, thus painting an inaccurately rosy picture of a drug's tolerability.

The structured support from nurses and doctors abruptly stops after major treatments like chemotherapy conclude. This creates a feeling of being orphaned, as patients lose their primary point of contact for ongoing side effects and fears, highlighting a critical gap in long-term survivorship care.

Oncology research is moving beyond standard quality-of-life metrics to study 'decision regret' and toxicity perception after adjuvant therapy is completed. This novel approach better captures the long-term psychological impact on patients, whose perspectives often change dramatically months or years after their initial treatment decision.

Optimal care involves introducing palliative services early—within eight weeks of diagnosis for advanced or recurrent endometrial cancer. This proactive approach focuses on symptom management and quality of life, not just end-of-life care, and can improve outcomes.

The RAS/MAP kinase pathway is an "underrecognized" and "underutilized" therapeutic target in endometrial cancers. Despite up to a quarter of these cancers having mutations in pathway genes, clinical focus has often been elsewhere. This highlights a significant, overlooked opportunity for applying RAS-targeted therapies to a broader patient population.

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.

Patients are often unprepared that finishing active treatment or achieving "no evidence of disease" is not the end of their struggle. Survivorship introduces a distinct phase of challenges, including managing long-term side effects, PTSD, and fear of recurrence, which requires different support.